Theracos

• NCT03167411

  Phase 1, Completed, 20 people, 30 May 2017

• NCT03115112

  Phase 3, Completed, 386 people, 14 Apr 2017

• NCT02956044

  Phase 1, Completed, 54 people, 4 Nov 2016

• NCT02769481

  Phase 3, Completed, 426 people, 11 May 2016

• Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2

  Consulting or advice, Fees or honoraria, Grants or research support, Board or leadership role, 17 Sept 2026

• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

  Consulting or advice, 20 Aug 2021

• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

  Grants or research support, 6 Aug 2021

• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

  Grants or research support, 27 Jun 2021

Sources: pubmed.ncbi.nlm.nih.gov